UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 79

Sortiert nach

Endoglin-targeted cancer therapy

Current drug delivery, 2011-01, Vol.8 (1), p.135

2011

Volltextzugriff (PDF)

Anti‐endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature

International journal of cancer, 2009-09, Vol.125 (6), p.1446-1453

2009

Volltextzugriff (PDF)

Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial

Communications medicine, 2023-09, Vol.3 (1), p.120-120, Article 120

2023

Volltextzugriff (PDF)

Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b

Leukemia research, 2024-01, Vol.136, p.107436-107436, Article 107436

2024

Volltextzugriff (PDF)

A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

Clinical cancer research, 2012-09, Vol.18 (17), p.4820-4829

2012

Volltextzugriff (PDF)

An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti‐Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma

The oncologist (Dayton, Ohio), 2019-02, Vol.24 (2), p.202-210

2019

Volltextzugriff (PDF)

An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer

Clinical cancer research, 2014-12, Vol.20 (23), p.5918-5926

2014

Volltextzugriff (PDF)

Facilitation of endoglin‐targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105)

International journal of cancer, 2015-01, Vol.136 (2), p.452-461

2015

Volltextzugriff (PDF)

Anti‐tumor activity of an anti‐endoglin monoclonal antibody is enhanced in immunocompetent mice

International journal of cancer, 2008-05, Vol.122 (10), p.2266-2273

2008

Volltextzugriff (PDF)

A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma

Clinical genitourinary cancer, 2017-02, Vol.15 (1), p.77-85

2017

Volltextzugriff (PDF)

Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody : Differences in growth rate and therapeutic response between tumors growing at different sites

International journal of oncology, 2006-11, Vol.29 (5), p.1087-1094

2006

Volltextzugriff (PDF)

Synergy between anti‐endoglin (CD105) monoclonal antibodies and TGF‐β in suppression of growth of human endothelial cells

International journal of cancer, 2004-01, Vol.108 (2), p.251-257

2004

Volltextzugriff (PDF)

Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin

Clinical cancer research, 2001-03, Vol.7 (3), p.524-532

2001

Volltextzugriff (PDF)

Induction of Lasting Complete Regression of Preformed Distinct Solid Tumors by Targeting the Tumor Vasculature Using Two New Anti-Endoglin Monoclonal Antibodies

Clinical cancer research, 1999-02, Vol.5 (2), p.371-382

1999

Volltextzugriff (PDF)

Antiangiogenic chimeric anti-endoglin (CD105) antibody : pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin

Cancer Immunology, Immunotherapy, 2006-02, Vol.55 (2), p.140-150

2006

Volltextzugriff (PDF)

Expression of endoglin (CD105) in tumor blood vessels

International journal of cancer, 2002-05, Vol.99 (2), p.310-311

Seon, Ben K.

2002

Volltextzugriff (PDF)

Receptor-targeted anticancer therapy

Immunologic research, 2010-03, Vol.46 (1-3), p.189-191

2010

Volltextzugriff (PDF)

Angiogenesis and metastasis marker of human tumors

Rinsho byori. The Japanese journal of clinical pathology, 2001-10, Vol.49 (10), p.1005

2001

Volltextzugriff (PDF)

Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105): Vascular Endoglin Targeting Cancer Therapy

International journal of cancer, 2015-01, Vol.136 (2), p.452-461

2015

Volltextzugriff (PDF)

Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide

Cancer research (Chicago, Ill.), 2001-11, Vol.61 (21), p.7846-7854

2001

Volltextzugriff (PDF)

A phase 2 trial of TRC105 with bevacizumab for bevacizumab refractory glioblastoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2035-2035

2016

Volltextzugriff (PDF)

A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.10514-10514

2015

Volltextzugriff (PDF)

A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.11016-11016

2016

Volltextzugriff (PDF)

A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.426-426

2015

Volltextzugriff (PDF)

A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with capecitabine for advanced solid tumors (including patients with progressive or recurrent HER2-negative metastatic breast cancer)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3057-3057

2013

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(74)

Publikationsform

Artikel
(77)
Tagungsberichte
(2)

Sprache

Englisch
(79)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Humans
(47)
Science & Technology
(44)
Life Sciences & Biomedicine
(40)
Animals
(31)
Oncology
(29)
Biological And Medical Sciences
(28)
Medical Sciences
(26)
Mice
(24)
Female
(17)
Antibodies, Monoclonal - Immunology
(16)
Endoglin
(16)
Pharmacology. Drug Treatments
(13)
Antineoplastic Agents
(12)
Cell Line
(12)
Mice, Inbred Balb C
(12)
Antibodies, Monoclonal - Therapeutic Use
(11)
Male
(11)
Antigens, Neoplasm - Immunology
(10)
Immunotherapy
(10)
Neoplasm Transplantation
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Endoglin-targeted cancer therapy

Anti‐endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature

Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial

Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b

A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti‐Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma

An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer

Facilitation of endoglin‐targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105)

Anti‐tumor activity of an anti‐endoglin monoclonal antibody is enhanced in immunocompetent mice

A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma

Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody : Differences in growth rate and therapeutic response between tumors growing at different sites

Synergy between anti‐endoglin (CD105) monoclonal antibodies and TGF‐β in suppression of growth of human endothelial cells

Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin

Induction of Lasting Complete Regression of Preformed Distinct Solid Tumors by Targeting the Tumor Vasculature Using Two New Anti-Endoglin Monoclonal Antibodies

Antiangiogenic chimeric anti-endoglin (CD105) antibody : pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin

Expression of endoglin (CD105) in tumor blood vessels

Receptor-targeted anticancer therapy

Angiogenesis and metastasis marker of human tumors

Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105): Vascular Endoglin Targeting Cancer Therapy

Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide

A phase 2 trial of TRC105 with bevacizumab for bevacizumab refractory glioblastoma

A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS)

A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS)

A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma

A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with capecitabine for advanced solid tumors (including patients with progressive or recurrent HER2-negative metastatic breast cancer)

Suchergebnisse filtern